Eco Animal Health Group PLC Block listing Interim Review

RNS Number : 8444C

Eco Animal Health Group PLC

12 February 2024

 

 

 

 

ECO Animal Health Group PLC

 

BLOCK LISTING RETURN

 

Date: 12 February 2024

 

Name of applicant:		ECO Animal Health Group plc
Name of scheme:		Executive Share Option Scheme and Unapproved Share Option Scheme
Number and class of securities originally listed and the date of admission:		1,500,000 ordinary shares of 5 pence each on 20 July 2017
Period of return:	From:	1 November 2022	To:	09 February 2024
Balance of unallotted securities under scheme(s) from previous return:		375,505
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0
Less:  Number of securities issued/allotted under scheme(s) during period:		0
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		375,505

 

-Ends-

For further information please contact:

 

ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO) 020 8447 8899   Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies Sam Butcher 020 7496 3000 Investec (Joint Broker) Gary Clarence Lydia Zychowska 020 7597 5970     Equity Development Hannah Crowe Matt Evans 020 7065 2692 ICR Consilium (Financial PR) Mary-Jane Elliott Jessica Hodgson 020 3709 5700 [e-mail]

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

BLRGPUMWPUPCGPP